BIAS NOTICE
Encode may hold positions in covered names, may have current or past compensated relationships, and may be pursuing such relationships. Assume bias. See encodelp.com/disclosure for specifics.
An interview with Gideon Shapiro, Co-Founder & VP of Discovery at Bright Minds Biosciences, where we discuss recent and upcoming events in psychedelic drug development. We cover Bright Minds pipeline of 5HT2 agonists, the importance of FDA’s approval of Spravato, and Compass’s impending Ph2b psilocybin data, among other topics relevant in the psychedelic space.
To listen on Podbean click here
Apple Podcasts here
Spotify click here
YouTube click here
Treat what you read here as biased. Encode Ideas, LP and its principals may hold positions in any company covered, may have current or past compensated relationships with covered companies, and may be pursuing such relationships. Our analysis is influenced by all of the above - actual positions, current relationships, past relationships, and prospective relationships. Assume errors. Nothing herein is investment advice. See encodelp.com/disclosure for current and past sponsor relationships.
